Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Essential Therapeutics (ETRX) formerly Microcide (MCDE -- Ignore unavailable to you. Want to Upgrade?

To: Mark Adams who wrote (184)	4/5/1999 10:55:00 AM
From: SemiBull	Read Replies (1) \| Respond to of 415

Jubak's Journal Seven top biotech picks for 1999 I'm adding two more stocks to my biotech portfolio -- like the first five, they're cheap, have lots of cash and pack plenty of promise in the pipeline. (see moneycentral.msn.com Microcide Pharmaceuticals Price (3/4/99): $4.06 Market cap.: $44 million Cash on hand: $33 million Admittedly, Microcide is a very early stage biotech company. But I like the risk/reward potential. The company specializes in developing drugs that will kill bacteria that have developed resistance to existing antibiotics. That's a huge potential market as reports show that bacteria are increasingly immune to even the most powerful of the current generation of drugs. Johnson & Johnson (JNJ) is working with Microcide on drugs to attack resistant staphylococcus and enterococcus strains. Pfizer expanded its research deal with Microcide in 1998 to include the development of new antibiotics for animals. That's all potential, I grant, but with almost $3 a share in cash behind a $4 stock, these shares don't carry much risk.